Tofacent is identified for this website as a product containing 5 mg of tofacitinib. Product-specific information concerning the manufacturer, dosage form, authorization and commercial supply chain requires verification.
Tofacitinib is a JAK inhibitor that modifies signaling pathways involved in immune and inflammatory responses. The medicine is marketed internationally under the reference brand XELJANZ.
Product identity
| Attribute | Information |
|---|---|
| Product | Tofacent |
| Active ingredient | Tofacitinib |
| Stated strength | 5 mg |
| Drug class | JAK inhibitor |
| Therapeutic category | Immunomodulatory medicine |
| Dosage form | 5 mg twice daily for adults |
| Manufacturer | Incepta Pharmaceuticals Ltd. |
| Marketing authorization holder | Incepta Pharmaceuticals Ltd. |
| Reference product | XELJANZ |
| Originator/developer | Pfizer |
The current U.S. XELJANZ label identifies 5 mg and 10 mg immediate-release tablets, 11 mg and 22 mg extended-release tablets, and a 1 mg/mL oral solution.
Those reference-product presentations should not automatically be attributed to Tofacent without product-specific documentation.
Tofacent and XELJANZ
XELJANZ is the established Pfizer reference brand for tofacitinib. The existence of the same active ingredient does not by itself establish that Tofacent and XELJANZ have identical formulation, excipients, manufacturing arrangements or regulatory status.
What does 5 mg mean?
A 5 mg strength indicates the stated amount of tofacitinib in the dosage unit. The appropriate regimen depends on the indication, formulation, age, kidney and liver function, concomitant medicines and applicable prescribing information.
Professional supervision
Tofacitinib affects immune-system signaling and can increase the risk of serious infections and other clinically important adverse outcomes. Appropriate screening and monitoring are therefore part of treatment.